Soon-Shiong

Rank #732

UNITED STATES•Healthcare•Pharmaceuticals

Patrick Soon-Shiong

Net Worth

$5.468B

-0.27% (24h)

Dr. Patrick Soon-Shiong, a South African-born American, is a prominent figure in the healthcare industry, with an estimated net worth of $5.6 billion. His wealth stems primarily from pharmaceuticals. He is a physician, surgeon, scientist, and entrepreneur. His career includes inventing the cancer drug Abraxane. He is the founder of NantWorks, a network of healthcare and technology startups. He is an Executive Chairman at ImmunityBio. With over 850 patents, he has made significant contributions to medical research and innovation.

The Full Dossier

Early Life and Education

Patrick Soon-Shiong was born in Port Elizabeth, South Africa, on July 29, 1952, to Chinese immigrant parents. He displayed exceptional academic abilities from an early age. He graduated from the University of Witwatersrand with a medical degree (MBBCh) at the age of 23. He furthered his education with a Master's degree in Surgery from the University of British Columbia.

Rise to Success

Soon-Shiong's career includes significant roles as a surgeon and entrepreneur. He performed the first whole-pancreas transplant at UCLA and developed the drug Abraxane, a breakthrough in cancer treatment. He founded several companies, including American Pharmaceutical Partners and Abraxis BioScience, later sold for billions. He is currently the Executive Chairman, Global Chief Medical & Technology Officer at ImmunityBio.

Key Business Strategies

Soon-Shiong's business strategy involves innovation in pharmaceuticals and healthcare technology. He founded NantWorks, a network of healthcare, biotech, and AI startups. His focus is on integrating advanced technologies to improve healthcare delivery and patient outcomes. He has invested in companies focused on developing cancer drugs and creating advanced healthcare infrastructure.

Philanthropy

Soon-Shiong is also known for his philanthropic efforts through the Chan Soon-Shiong Family Foundation. The foundation concentrates its efforts on medical technology projects and improving access to medical services in underserved populations, having pledged over $1 billion to these causes.

Career Timeline

2024

Anktiva Approval

Received US FDA approval for a new class of immunotherapy drug called Anktiva in non-muscle invasive bladder cancer.

2018

Purchased Los Angeles Times

Purchased the Los Angeles Times and San Diego Union-Tribune.

2011

Founded NantWorks

Founded NantWorks, whose mission was to converge ultra-low power semiconductor technology, supercomputing, high performance, secure advanced networks and augmented intelligence to transform how we work, play, and live.

2010

Sold Abraxis BioScience

Sold Abraxis BioScience to Celgene.

2007

Founded NantHealth

Founded NantHealth to provide fiber-optic, cloud-based data infrastructure to share healthcare information.

2005

Abraxane Approval

The FDA approved Abraxane, a cancer treatment developed by Soon-Shiong.

1998

Purchased Fujisawa

Purchased Fujisawa, a company that sold injectable generic drugs.

1991

Founded VivoRx Inc.

Founded VivoRx Inc., a biotechnology firm that would later lead to the founding of APP Pharmaceuticals in 1997.

1984

Board Certified Surgeon

Became a board-certified surgeon in the United States.

1975

Medical Degree

Graduated with a medical degree from the University of Witwatersrand, Johannesburg.

Philanthropic Impact

Medical Research and Access$1B+

Chan Soon-Shiong Family Foundation

Focuses on medical technology projects and improving access to medical services.